Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer

IMPORTANCE: To date, limited studies have examined the comparative outcomes of pertuzumab treatment in the real-world setting. End-of-study analyses of the CLEOPATRA trial found median overall survival (OS) of 57.1 months in patients receiving pertuzumab compared with 40.8 months in control patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Wei Fang, Beca, Jaclyn M., Nagamuthu, Chenthila, Liu, Ning, de Oliveira, Claire, Earle, Craig C., Trudeau, Maureen, Mercer, Rebecca E., Chan, Kelvin K. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886524/
https://www.ncbi.nlm.nih.gov/pubmed/35226087
http://dx.doi.org/10.1001/jamanetworkopen.2021.45460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886524/
https://www.ncbi.nlm.nih.gov/pubmed/35226087
http://dx.doi.org/10.1001/jamanetworkopen.2021.45460

Ejemplares similares